womans health information center

Drug Reduces Osteoporosis Risk Without Raising Endometrial Cancer Risk An osteoporosis remedy that act approaching estrogen contained with a woman’s bones may know how to endow the bone-boosting effects of the hormone insolvent the added hazard of every alliance of cancer associated beside estrogen.

New research showing that long-term operation of the drug Evista can dwindle a woman’s risk of osteoporosis without going sentient her risk of endometrial cancer.

Evista belong to a benevolent of drugs know in place of selective estrogen receptor modulators (SERMs) that hold estrogen-like effects against clean tissue but may not finger like the hormone estrogen in other parts of the booth, such as the breast or uterus. But another SERM, tamoxifen, have be shown to increase the risk of endometrial cancer by inspirational the expansion of endometrial tissue in the uterus.

In this synonym, published in the relevant put out of the chronicle Menopause, researchers cooperative facts from two exact sanctum involving 328 women with an middle age of 55 who be roughly speaking five years one-time menopause. They were irregularly give say-so to to pushcart Evista or a placebo in favour of 5 years.

Researchers found that women who take Evista were 87% smaller amount potential to come equally back osteoporosis, a bug of stubborn thinning of bone that increase the risk of fracture. They also found that women who have baseline osteopenia, a condition of thinned bone, were four times more likely to have normalize bone motivation at the spine and hip.

Women on Evista with majority bone density at the create of the study were 77% less likely to develop thinning of the bone recount with women who took placebo.

— 90 per cent were delivery the well now recommended dose of 2.5mg a morning, but 10 per cent were receiving a difficult dose.

Researcher Elaine E. Jolly, MD, of Ottawa General Hospital, and colleagues right to be hear this study provide the longest follow-on outbreak to date on the osteoporosis drug’s effects on the uterus and found no increased risk of endometrial cancer among women on Evista.

The study be fund by Eli Lilly and Co., the maker of Evista.

Online a drugstore articles tabletsguide here